
Zynerba Pharmaceuticals ZYNE
Quarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals Long Term Debt Current 2011-2026 | ZYNE
Annual Long Term Debt Current Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 215 K | 209 K | 110 K | 244 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 244 K | 110 K | 194 K |
Long Term Debt Current of other stocks in the Drug manufacturers industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
5.36 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.19 | 3.48 % | $ 128 M | ||
|
China Pharma Holdings
CPHI
|
39.3 K | $ 0.61 | -1.46 % | $ 10.7 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
357 K | $ 3.9 | 1.56 % | $ 54.8 M | ||
|
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
Evoke Pharma
EVOK
|
13.4 K | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
3.91 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
1.38 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
3.5 M | $ 10.91 | -0.27 % | $ 559 M | ||
|
Harrow Health
HROW
|
806 K | $ 52.51 | 1.86 % | $ 1.71 B | ||
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
1.72 M | $ 4.3 | -0.69 % | $ 267 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.44 | 2.5 % | $ 402 M | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
Jupiter Wellness
JUPW
|
213 K | - | - | $ 33.6 M | ||
|
Bausch Health Companies
BHC
|
61 M | $ 6.04 | 0.83 % | $ 2.2 B | ||
|
Sundial Growers
SNDL
|
34.3 M | $ 1.55 | 4.03 % | $ 3.37 M | ||
|
Neoleukin Therapeutics
NLTX
|
2.56 M | - | - | $ 193 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 23.39 | 1.21 % | $ 1.08 B | ||
|
Organogenesis Holdings
ORGO
|
4.27 M | $ 4.01 | 2.42 % | $ 528 M | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
27.8 M | $ 14.63 | 0.48 % | $ 2.01 B | ||
|
Aurora Cannabis
ACB
|
5.38 M | $ 3.8 | 4.11 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
301 K | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
1.38 M | $ 0.94 | 1.95 % | $ 21.9 M | ||
|
Tilray
TLRY
|
2.47 M | $ 7.89 | 4.44 % | $ 4.88 B | ||
|
OptiNose
OPTN
|
911 K | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
928 K | $ 12.04 | - | $ 855 M | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 2.83 | -0.35 % | $ 3.51 M | ||
|
Solid Biosciences
SLDB
|
1.79 M | $ 6.17 | 5.11 % | $ 252 M | ||
|
SCYNEXIS
SCYX
|
340 K | $ 0.8 | 3.91 % | $ 38.3 M | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
Veru
VERU
|
1.07 M | $ 2.63 | 6.05 % | $ 355 M | ||
|
TherapeuticsMD
TXMD
|
1.47 M | $ 2.25 | -1.32 % | $ 23.5 M | ||
|
cbdMD
YCBD
|
98.7 K | $ 0.92 | 0.72 % | $ 3.97 M | ||
|
Viatris
VTRS
|
80.6 M | $ 16.15 | 1.22 % | $ 19.6 B |